RAPTAMER DISCOVERY GROUP
"Raptamer Discovery Group ™ Raptamers ™ - Next-Generation Aptamers Raptamer Discovery Group ™ specializes in the rapid development of Raptamers ™ –next-generation DNA molecules. Raptamers ™ are uniquely modified, short strings of DNA (called aptamers) capable of binding to a designated protein or molecular target. Raptamers ™ bind with incredible strength—up to 1700x stronger than current aptamer technology—without binding to undesired targets. Customers will use this technology to progress their biotechnology programs, including drug development, radiologic imaging, laboratory diagnostics, and research tool development."
RAPTAMER DISCOVERY GROUP
Industry:
Biotechnology Life Science Pharmaceutical
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.raptamer.com
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Official Site Inspections
http://www.raptamer.com
- Host name: 198.185.159.144
- IP address: 198.185.159.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Raptamer Discovery Group"
Raptamer Therapeutics
Novel peptide-oligonucleotide hybrid therapeutics for precision medicine. © Raptamer Therapeutics 2024. All rights reserved.See details»
Aptamer Group
Aptamer Group is a leading provider of custom Optimer ® selection and development services. Optimer binders are next-generation aptamers …See details»
SBIR-STTR-Tibbetts Award Winner - AM Biotechnologies, LLC …
Jun 23, 2022 · Raptamer Discovery Group specializes in the development of next-generation, highquality DNA molecules – called Raptamersâ„¢ – that can be used as therapeutic, …See details»
Raptamer Discovery Group - Crunchbase Company Profile
Raptamers â„¢ are uniquely modified, short strings of DNA (called aptamers) capable of binding to a designated protein or molecular target. Raptamers â„¢ bind with. incredible strength—up to …See details»
Raptamer Discovery Group, LLC - LinkedIn
Raptamer Discovery Group, LLC is dedicated to the development and commercialization of aptamer technology and its products. Specifically, we develop synthetic affinity reagents called...See details»
Abstract 3210: Raptamer-drug conjugates as molecularly targeted …
Mar 22, 2024 · Here, we present a new therapeutic approach that targets COF-01-positive cancer cells using next generation aptamer conjugates. We performed a cell- and protein-based …See details»
Fannin Partners, University of Texas MD Anderson Cancer Center …
Aug 28, 2024 · Two Houston organizations announced a new collaboration in a major move for Houston’s biotech scene. Fannin Partners and the University of Texas MD Anderson Cancer …See details»
Raptamer Discovery Group Company Profile - Office Locations
Raptamer Discovery Group is a company developing aptamers with a backbone made up of standard DNA nucleotides. It helps to find binding molecules for research or commercial …See details»
RePORT 〉 RePORTER - National Institutes of Health
PROJECT SUMMARY: Fannin Innovation Studio is developing a new discovery proteomics platform called the Unified Process that identifies potential biomarkers in biological samples …See details»
Raptamer-Drug Conjugates as Molecularly Targeted Cancer …
We have generated next-generation ssDNA aptamers (Raptamers) using a novel approach that utilizes our proprietary bead-based oligonucleotide libraries. Raptamers contain side chain …See details»
Aptamer - Wikipedia
Aptamers are oligomers of artificial ssDNA, RNA, XNA, or peptide that bind a specific target molecule, or family of target molecules. They exhibit a range of affinities (K D in the pM to μM range), [1][2] with variable levels of off-target …See details»
Champions Oncology Announces a Partnership with Fannin
Jan 20, 2022 · Houston-based Raptamer Discovery Group (RDG), a Fannin portfolio company, will provide key services to Fannin in the co-development process. RDG specializes in the …See details»
Raptamer-Drug Conjugates as Molecularly Targeted Cancer …
Raptamers that can bind tumor antigens such as COF-01, with high affinity and specificity are well-suited for development of Raptamer-drug conjugates (RapDCs). We have developed a …See details»
Aptamers as therapeutics | Nature Reviews Drug Discovery
Aug 1, 2010 · Aptamers are discovered using SELEX (systematic evolution of ligands by exponential enrichment), a directed in vitro evolution technique in which large libraries of …See details»
Raptamer Discovery Group - Tibbetts Awards
Raptamer Discovery Group specializes in the development of next-generation, high-quality DNA molecules – called Raptamersâ„¢ – that can be used as therapeutic, diagnostic, or research …See details»
Aptamer-Based Targeted Protein Degradation | ACS Nano
Mar 21, 2023 · In this perspective, we provide a brief introduction to TPD technology in its current progress, and we summarize its application challenges. Recent advances in aptamer-based …See details»
Abstract 456: Raptamer-drug conjugates as molecularly targeted …
Apr 4, 2023 · Anti-COF-01 Raptamer-drug conjugates (Rap-DCs) were developed by conjugating the Raptamers to monomethyl auristatin F via a cleavable linker. In vitro efficacy data has …See details»
Award - SBIR
PROJECT SUMMARY: Fannin Innovation Studio is developing a new discovery proteomics platform called the Unified Process that identifies potential biomarkers in biological samples …See details»
Foremost Companies in the Aptamers Market: Raptamer Discovery …
Raptamer Discovery Group (US) has focused on developing next-generation aptamers for diagnostic and therapeutic applications. The company employs Raptamer technology for …See details»
Abstract 3210: Raptamer-drug conjugates as ... - Semantic Scholar
Here, we present a new therapeutic approach that targets COF-01-positive cancer cells using next generation aptamer conjugates. We performed a cell- and protein-based selection using …See details»